Google Ventures' reported $100 million investment in oncology Big Data startup Flatiron Health came to fruition this week. And the deal is even bigger than early reports suggested, with Flatiron raising $130 million and buying electronic medical record business Altos Solutions.
UCLA brainchild ImaginAb has hauled in another $21 million in venture cash to advance its antibody-re-engineering technology, a biotech approach to imaging that the company believes will help personalize treatments for cancer and immune disease.
A spinoff from the Ecole Polytechnique Fédérale de Lausanne has rounded up a hefty $37.5 million A round from a prominent group of biotech investors to develop a new-and-improved portfolio of immune-tolerant therapies.
After recruiting a chief scientific officer from Epizyme, upstart cancer drug developer Loxo Oncology has nabbed a $24 million B round from some marquee venture players. New Enterprise Associates came in to lead this round, buying into the business plan of focusing on genetically-defined cancers, with existing investors Aisling Capital and OrbiMed Advisors joining in.
Evanston, IL's Naurex nailed down another $25 million in venture funding to accelerate its two-pronged depression program, posting positive midstage results for its top prospect.
Paris-based Enterome Bioscience, focused on the gut microbiome, has raised €10 million ($11.5 million) in the first tranche of its Series B fundraising. Seventure (including from its new Health for Life Capital fund), Lundbeckfond Ventures and Omnes Capital contributed cash to the deal.
Lightstone Ventures, the life sciences-focused progeny of two VC stalwarts, has wrapped up a fund of its own, setting out with $172 million to back early-stage drug and med tech companies.
San Diego's Otonomy has hauled in another $49 million to advance its therapies for ear disorders, hoping to do for hearing-robbing ailments what VEGF inhibitors did for eye diseases.
After shifting its focus to immuno-oncology last year, Germany's Isarna Therapeutics has pulled down $7.6 million to jump-start the development of some preclinical cancer candidates.
Stalwart biotech investor Arch Venture Partners is putting together a $250 million 8th fund, according to a regulatory filing, piling on to the roughly $1.5 billion it currently manages.